

# RSC | Advancing the Chemical Sciences

## Programme for Cancer Chemistry Meeting at The School of Pharmacy, London Thursday 6<sup>th</sup> January 2011

09.30 – 10.00	Registration/Coffee
10.10 – 10.15	Welcome – Professor Stephen Neidle (School of Pharmacy)
Session 1	Chair, Professor Roger Griffin (Northern Cancer Institute)
10.15 – 11.00	Professor Barry Potter (University of Bath) Royal Society of Chemistry Interdisciplinary Research Award Winner <i>“Sulfatase Inhibitors: From Concept to Clinic”</i>
11.00 – 11.20	Contributed Talk 1 – AstraZeneca <i>Title to be confirmed.</i>
11.20 – 11.45	Refreshments/Posters
11.45 – 12.30	Professor Maurizio Botta (University of Sienna) <i>“Three different approaches to target the T315I mutation: ATP-competitive, ATP-non-competitive and 14-3-3 inhibitors”</i>
12.30 – 12.50	Dr Marco Wenzel (University of Southampton) <i>“Transmembrane Transporters for Chloride and Bicarbonate”</i>
12.50 – 1.10	Dr Shudong Wang (University of Nottingham) <i>“Discovery of CDK9 Inhibitors for the Treatment of Cancer”</i>
1.10 – 2.00	Lunch/Posters
Session 2	Chair, Dr Tony Raynham (Cancer Research Technology)
2.00 – 2.45	Professor Andrew Hamilton (University of Oxford) <i>“Targeting Protein Surfaces Using Designed Proteomimetics”</i>
2.45 – 3.30	Professor Paul Workman (Institute of Cancer Research) Royal Society of Chemistry George and Christine Sosnovksy Cancer Research Award Winner <i>“Exploiting the cancer genome: Design of chemical probes and molecularly targeted drugs”</i>

AstraZeneca 

CANCER RESEARCH UK 

<b>3.30 – 3.50</b>	<b>Tea/Posters</b>
<b>3.50 – 4.10</b>	<b>Dr Giovanna Zinzalla (School of Pharmacy)</b> <b><i>“The Chemistry of Targeting Protein-Protein Interactions for Drug Discovery: Thinking Outside of the Box”</i></b>
<b>4.10 – 4.30</b>	<b>Dr Kamyar Afarinkia (University of Bradford)</b> <b><i>“Tools for a Glycomic Approach to Cancer Drug Discovery: Diversity Oriented Synthesis of Pseudosugars”</i></b>
<b>4.30 – 4.50</b>	<b>Dr Katja Strohfeldt-Venables (University of Reading)</b> <b><i>“Novel Titanium-based Anti-cancer Drugs”</i></b>
<b>4.50 – 5.10</b>	<b>Dr Gareth Pritchard (Loughborough University)</b> <b><i>Title to be confirmed.</i></b>
<b>5.10 – 5.30</b>	<b>Dr John Spencer (University of Greenwich)</b> <b><i>“Hybrid Anticancer Agents Targeting HDACs”</i></b>
<b>5.30</b>	<b>Closing Comments</b>

We are grateful for the additional support of Cancer Research UK and AstraZeneca